公开(公告)号：US10780119B2

公开(公告)日：2020-09-22

申请号：US15989098

申请日：2018-05-24

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. Webster ,  Rajesh Sharma ,  Gary Chiang

IPC: A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/73 ,  C07K14/16 ,  C07K14/705 ,  C12N5/0783 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501 ,  A61K45/06

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

公开(公告)号：US11564947B2

公开(公告)日：2023-01-31

申请号：US17025607

申请日：2020-09-18

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. Webster ,  Rajesh Sharma ,  Gary Chiang

IPC: C07H21/04 ,  A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/73 ,  C07K14/16 ,  C07K14/705 ,  C12N5/0783 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501 ,  A61K45/06

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.